Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 6/20 | 0.64 |
| ▸ | CA2 | P00918 | 6/20 | 0.64 |
| ▸ | ACHE | P22303 | 6/20 | 0.64 |
| ▸ | DRD2 | P14416 | 7/20 | 0.53 |
| ▸ | DRD3 | P35462 | 4/20 | 0.53 |
| ▸ | DRD4 | P21917 | 2/20 | 0.53 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.51 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.45 |
| ▸ | BTK | Q06187 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9136687 | 1.00 | CA1 (0.64) | CA1CA2ACHEDRD2DRD3 | |
| SCHEMBL5722246 | 1.00 | CA1 (0.64) | CA1CA2ACHEDRD2DRD3 | |
| SCHEMBL7399411 | 0.95 | CA1 (0.64) | CA1CA2ACHEDRD2DRD3 | |
| SCHEMBL390212 | 0.89 | EPHX2 (0.51) | CA1CA2ACHEDRD2DRD3 | |
| SCHEMBL464262 | 0.86 | MTNR1A (0.50) | CA1CA2ACHEDRD2MTNR1A | |
| SCHEMBL9752143 | 0.86 | MTNR1A (0.50) | CA1CA2ACHEDRD2MTNR1A | |
| SCHEMBL9752147 | 0.86 | MTNR1A (0.50) | CA1CA2ACHEDRD2MTNR1A | |
| SCHEMBL9132121 | 0.84 | MTNR1A (0.48) | CA1CA2ACHEDRD2MTNR1A | |
| SCHEMBL9133654 | 0.84 | MTNR1A (0.48) | CA1CA2ACHEDRD2MTNR1A | |
| SCHEMBL10253259 | 0.84 | MTNR1A (0.51) | CA1CA2ACHEDRD2MTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0893432-B1 | PHENYLETHANOLAMINOTETRALINCARBOXAMIDE DERIVATIVES | KISSEI PHARMACEUTICAL (JP) | 2006-11-08 | — | — | EP | disclosed |
| US-7030160-B2 | Propanolaminotetralines, preparation thereof and compositions containing same | SANOFI-AVENTIS (FR) | 2006-04-18 | — | — | US | disclosed |
| US-20040034070-A1 | Propanolaminotetralines, preparation thereof and compositions containing same | SANOFI-AVENTIS (FR) | 2004-02-19 | — | — | US | disclosed |
| EP-1292572-B1 | PROPANOLAMINOTETRALINES, PREPARATION THEREOF AND COMPOSITIONS CONTAINING SAME | SANOFI SYNTHELABO (FR) | 2004-02-18 | — | — | EP | disclosed |
| CN-1100032-C | 3,4-disubstituted phenylethanolaminotetra lincarboxamide derivatives | KISSEI PHARMACEUTICAL (JP) | 2003-01-29 | — | — | CN | disclosed |
| EP-0882704-B1 | 3,4-DISUBSTITUTED PHENYLETHANOLAMINOTETRALINCARBOXAMIDE DERIVATIVES | KISSEI PHARMACEUTICAL (JP) | 2002-10-09 | — | — | EP | disclosed |
| EP-0894787-B1 | 3,4-DISUBSTITUTED PHENYLETHANOLAMINOTETRALINCARBOXYLATE DERIVATIVES | KISSEI PHARMACEUTICAL (JP) | 2002-06-12 | — | — | EP | disclosed |
| US-6136852-A | 3,4-disubstituted phenylethanolaminotetralincarboxylic acid derivatives | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2000-10-24 | — | — | US | disclosed |
| US-6133266-A | 3,4-disubstituted phenylethanolaminotetralincarboxamide derivatives | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2000-10-17 | — | — | US | disclosed |
| US-6046192-A | Phenylethanolaminotetralincarboxamide derivatives | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2000-04-04 | — | — | US | disclosed |
| EP-0882704-A1 | 3,4-DISUBSTITUTED PHENYLETHANOLAMINOTETRALINCARBOXAMIDE DERIVATIVES | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 1998-12-09 | — | — | EP | disclosed |
| US-5449813-A | Phenylethanolamino- and phenylethanolaminomethyl-tetralines, process for the preparation thereof, intermediates in said process and pharmaceutical compositions containing them | SANOFI (FR) | 1995-09-12 | — | — | US | disclosed |
| US-5401879-A | Phenylethanolamino- and phenylethanolaminomethyltetralines, process for the preparation thereof, intermediates in said process and pharmaceutical compositions containing them | SANOFI (FR) | 1995-03-28 | — | — | US | disclosed |
| EP-0347313-B1 | 2-Amino-7-hydroxytetraline ethers | SANOFI ELF (FR) | 1993-12-15 | — | — | EP | disclosed |
| US-5210276-A | PHENYLETHANOLAMINO- AND PHENYLETHANOLAMINOMETHYL-TETRALINES, PROCESS FOR THE PREPARATION THEREOF, INTERMEDIATES IN SAID PROCESS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ELF SANOFI (FR) | 1993-05-11 | — | — | US | disclosed |
| US-5202466-A | 2-amino-7-hydroxytetraline ethers | SANOFI (FR) | 1993-04-13 | — | — | US | disclosed |
| US-5159103-A | 2-amino-7-hydroxytetraline ethers | SANOFI (FR) | 1992-10-27 | — | — | US | disclosed |
| EP-0500443-A1 | Phenylethanolamino- and phenylethanolaminomethyltetralines, process for their preparation, intermediates of this process and pharmaceutical compositions containing them | SANOFI (FR) | 1992-08-26 | — | — | EP | disclosed |
| EP-0499755-A1 | Phenylethanolaminotetralines, process for their preparation, intermediates of this process and pharmaceutical compositions containing them | MIDY S.p.A. (IT) | 1992-08-26 | — | — | EP | disclosed |
| EP-0347313-A2 | 2-Amino-7-hydroxytetraline ethers | ELF SANOFI (FR) | 1989-12-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034070-A1 | Propanolaminotetralines, preparation thereof and compositions containing same | ADRB3, ADRB1, ADRB2 | CA1 4712/4885CA2 3342/4885ACHE 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.